雷公藤多苷联合咪唑斯汀治疗皮炎湿疹患者的临床价值

Clinical value of tripterygium glycosides combined with mizolastine in the treatment of patients with dermatitis and eczema

目的 探讨雷公藤多苷联合咪唑斯汀治疗皮炎湿疹患者的临床价值。方法 选取2016年1月至2019年12月本院收治的92例皮炎湿疹患者作为研究对象,采取随机数字表法分为两组,每组46例。对照组给予咪唑斯汀缓释片治疗,观察组在对照组基础上给予雷公藤多苷治疗,比较两组临床疗效、炎症因子指标[白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]及不良反应发生情况。结果 观察组治疗总有效率为97.83%,高于对照组的84.78%,差异有统计学意义(P<0.05)。治疗后,两组IL-2、IL-6、CRP水平均明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.52%,对照组不良反应发生率为8.70%,组间比较差异无统计学意义。结论 雷公藤多苷联合咪唑斯汀治疗皮炎湿疹,可提高临床疗效,改善炎症因子水平,且不增加不良反应,值得临床推广应用。

Objective To investigate the clinical value of tripterygium glycosides combined with mizolastine in the treatment of patients with dermatitis and eczema. Methods A total of 92 patients with dermatitis and eczema who were admitted to our hospital from January 2016 to December 2019 were selected as the research subjects, and they were divided into two groups according to random number table method, with 46 cases in each group. The control group was treated with mizolastine sustained-release tablets, and the observation group was treated with tripterygium glycosides on the basis of the control group, the clinical efficacy, inflammatory factor indexes(interleukin-2 [IL-2], interleukin-6 [IL-6], C-reactive protein[CRP]) and the occurrence of adverse reactions were compared between the two groups. Results The total clinical effective rate in the observation group was 97.83%, which was higher than 84.78% in the control group, and the difference was statistically significant(P<0.05). After treatment,the levels of IL-2, IL-6 and CRP in the two groups were significantly lower than those before treatment, and the observation group were lower than the control group, and the difference was statistically significant(P<0.05). The total incidence of adverse reactions in the observation group was6.52%, and the total incidence of adverse reactions in the control group was 8.70%, and there was no significant difference between the two groups.Conclusion Tripterygium glycosides combined with mizolastine in the treatment of dermatitis and eczema can improve the clinical efficacy and the level of inflammatory factors without increasing adverse reactions, which is worthy of clinical application.